A Phase II Study of Bevacizumab and High-dose Interleukin-2 in Patients With Metastatic Renal Cell Carcinoma: A Cytokine Working Group (CWG) Study

作者：Dandamudi Uday B; Ghebremichael Musie; Sosman Jeffrey A; Clark Joseph I; McDermott David F; Atkins Michael B; Dutcher Janice P; Urba Walter J; Regan Meredith M; Puzanov Igor; Crocenzi Todd S; Curti Brendan D; Vaishampayan Ulka N; Cro**y Nancy A; Margolin Kim A; Ernstoff Marc S^*

来源：Journal of Immunotherapy, 2013, 36(9): 490-495.

DOI：10.1097/CJI.0000000000000003

• immunotherapy
• antiangiogenesis
• renal cell cancer
• interleukin-2

Overexpression of vascular endothelial growth factor in renal cell carcinoma (RCC) leads to angiogenesis, tumor progression, and inhibition of immune function. We conducted the first phase II study to estimate the efficacy and safety of bevacizumab with high-dose interleukin-2 (IL-2) therapy in patients with metastatic RCC. Eligible patients had predominantly clear cell metastatic RCC, measurable disease, a Karnofsky Performance Status of 80%, and adequate end-organ function. IL-2 (600,000 IU/kg) was infused intravenously every 8 hours (maximum 28 doses) during two 5-day cycles on days 1 and 15 of each 84-day course. Bevacizumab (10 mg/kg) was infused intravenously every 2 weeks beginning 2 weeks before initiating IL-2. Fifty of 51 eligible patients from 8 centers were enrolled. Median progression-free survival (PFS) was 11.2 months (90% confidence interval, 5.7-17.7), and 2-year PFS was 18% (90% confidence interval, 8%-27%). Responses included 4 complete (8%) and 11 partial (22%) responses. Toxicities did not exceed those expected from each agent alone. Combining IL-2 plus bevacizumab is feasible, with a response rate and PFS at least as high as reported previously for the single agents. The regimen did not appear to enhance the rate of durable major responses over that of IL-2 alone.

• 出版日期2013-12